Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: ValuEngine, Inc.
$25.00
Provider: Reuters Investment Profile
$20.00
Provider: Ford Investor Services, Inc.
$12.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

PTC Therapeutics Inc receives positive opinion from CHMP for Translarna


Friday, 23 May 2014 08:13am EDT 

PTC Therapeutics Inc:Following its request for re-examination, the Committee for Medicinal Products for Human Use (CHMP) of European Medicines Agency (EMA) has adopted positive opinion regarding application for conditional marketing authorization of Translarna (ataluren).Says for treatment of nonsense mutation Duchenne muscular dystrophy (nmDMD) in ambulatory patients aged five years and older. 

Company Quote

39.44
 --
20 Nov 2014